Last reviewed · How we verify
complicated skin and skin structure infections
Approved treatments
Clinical guidelines
- FDA label — 1L
Linezolid is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, or Streptococcus agalactiae. - FDA label — 1L
Meropenem for Injection, USP is indicated for the treatment of complicated skin and skin structure infections (cSSSI) due to specified pathogens. - FDA label — 1L
Meropenem for Injection, USP is indicated for the treatment of complicated appendicitis and peritonitis caused by specified pathogens. - FDA label — 1L
Meropenem for Injection, USP is indicated for the treatment of bacterial meningitis caused by specified pathogens.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- complicated skin and skin structure infections patent landscape — cliff calendar, originator estates, attackable patents
- complicated skin and skin structure infections treatment landscape brief
- complicated skin and skin structure infections treatment updates RSS
Frequently asked questions about complicated skin and skin structure infections
What are the treatment guidelines for complicated skin and skin structure infections?
FDA label publishes guidelines for complicated skin and skin structure infections. 4 guideline references tracked.
Related
- Treatment landscape: complicated skin and skin structure infections patent cliff · complicated skin and skin structure infections CI report
- All diseases: Browse the disease index · Disease landscape hub